A HIV Study Of A Fixed-Dose Combination Tablet In Antiretroviral Experienced Patients
Phase 3
Completed
- Conditions
- HIV InfectionInfection, Human Immunodeficiency Virus I
- First Posted Date
- 2002-09-23
- Last Posted Date
- 2020-03-24
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 240
- Registration Number
- NCT00046176
- Locations
- 🇵🇷
GSK Investigational Site, Rio Piedras, Puerto Rico
New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects
Phase 3
Completed
- Conditions
- Infection, Human Immunodeficiency Virus IHIV Infection
- First Posted Date
- 2002-09-04
- Last Posted Date
- 2020-03-24
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 166
- Registration Number
- NCT00044577
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2-18 Years
- First Posted Date
- 2002-07-10
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 69
- Registration Number
- NCT00040664
- Locations
- 🇪🇸
GSK Investigational Site, Valencia, Spain
Study Of Investigational Regimen Combining FDA Approved HIV Drugs In HIV Subjects Experiencing Early Virologic Failure
Phase 4
Completed
- Conditions
- HIV Infection
- First Posted Date
- 2002-06-03
- Last Posted Date
- 2015-04-08
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 100
- Registration Number
- NCT00038506
- Locations
- 🇺🇸
GSK Investigational Site, Green Bay, Wisconsin, United States
© Copyright 2025. All Rights Reserved by MedPath